1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124


Real-time Euronext Paris  -  05/25 11:35:28 am EDT
1.766 EUR   -1.89%
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
05/16Nicox Announces a New Governance Structure
05/16Nicox Announces a New Governance Structure
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

01/05/2022 | 01:31am EDT
Press Release
Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030

  • Patent coverage for ZERVIATE® (cetirizine ophthalmic solution), 0.24% in Europe until 2030
January 5, 2022 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that patent EP2408453, covering the company’s product ZERVIATE® (cetirizine ophthalmic solution), 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of ZERVIATE which is commercialized in the U.S. by our exclusive U.S. licensee Eyevance Pharmaceuticals, and its use in the treatment of the symptoms of allergic conjunctivitis or allergic rhinoconjunctivitis. The prescription market for allergic conjunctivitis products in Europe, Eastern Europe and Turkey was estimated by IQVIA as around €260 million in 2020. The European Patent grants exclusivity until 2030, meaning that the ZERVIATE formulation is protected by granted patents in the U.S. to 2032, and in Europe, Japan and Canada to 2030.

“The European patent grant means that ZERVIATE now has patent coverage in all the principal pharmaceutical markets worldwide. We are working with our existing partners to bring ZERVIATE to commercialization and continue to look for additional licensing opportunities to broaden the ZERVIATE franchise. said Gavin Spencer, Chief Business Officer of Nicox.   The data package from the U.S. New Drug Application facilitates further approvals of ZERVIATE. We also collaborate with partners to ensure any necessary additional regulatory data are generated. In China, where ZERVIATE is partnered with Ocumension Therapeutics, for instance, pivotal Phase 3 data is being gathered to support local regulatory approval.”

ZERVIATE is commercialized in the U.S. by our exclusive U.S. partner Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd of Japan. ZERVIATE is also exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese and the majority of the Southeast Asian markets, to Samil Pharmaceutical in South Korea, to ITROM Pharmaceutical Group in certain Gulf and Arab markets, and to Laboratorios Grin in Mexico.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage

Bryan, Garnier & Co         Dylan van Haaften        Paris, France
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Damien Choplain        Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
LifeSci Advisors, LLC
Sophie Baumont
T +33 (0)6 27 74 74 49
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 and in the 2nd chapter of the amendment to the “Document d’Enregistrement Universel, rapport financier annuel et rapport de gestion 2020” filed with the AMF on December 9, 2021 which are available on Nicox’s website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99



  • EN_ZERVIATE Patent EU PR_20220105_F1

Primary Logo

Source: NICOX

2022 GlobeNewswire, Inc., source Press Releases

All news about NICOX SA.
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
05/16Nicox Announces a New Governance Structure
05/16Nicox Announces a New Governance Structure
05/16Nicox S.A. Announces Executive Changes
05/04NICOX : 2022 Ordinary Shareholder Meeting
05/04NICOX : 2022 Ordinary Shareholder Meeting
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
04/28Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr..
04/11Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
More news
Sales 2022 9,03 M 9,68 M 9,68 M
Net income 2022 -20,3 M -21,8 M -21,8 M
Net cash 2022 2,49 M 2,67 M 2,67 M
P/E ratio 2022 -3,83x
Yield 2022 -
Capitalization 77,8 M 83,5 M 83,5 M
EV / Sales 2022 8,35x
EV / Sales 2023 6,72x
Nbr of Employees 33
Free-Float 89,6%
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,80 €
Average target price 11,50 €
Spread / Average Target 539%
EPS Revisions
Managers and Directors
Michele Garufi Chairman & Chief Executive Officer
Sandrine Gestin Vice President-Finance
José Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Jean-François Labbé Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-29.55%83
MERCK KGAA-22.86%81 684
KYOWA KIRIN CO. LTD.-12.79%11 611